Within this testing model BRAF (serine/threonine-protein kinase B-Raf) and NRAS (neuroblastoma RAS viral oncogene homolog) mutations are sequentially investigated for diagnostic purposes, as 70% of melanomas detect BRAF and NRAS as common driver mutations [19]. The gene discussed is NRAS; the disease is melanoma.